Omixon is a global molecular diagnostics company, empowering clinical labs with technologies to improve patient outcomes by commercializing disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
As a software engineer I know from day one that reusable components are our best friends. Gradual development of the product – which is really possible with software unlike many other things – helps dealing with the constantly changing and …more
Omixon announce today a new partnership with Commugene in South Korea. Through our cooperation, from one of the fastest growing markets in the world, researchers in the biotechnology industry will have easier access to Omixon’s high-performance, high-throughput and high-resolution multi-sample kit and software only …more